Lexeo Reports Positive Interim Data Across All Dose Cohorts Of LX2006 - Quick Facts
(RTTNews) - Lexeo Therapeutics (LXEO) reported positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia cardiomyopathy. In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigator-initiated Pha
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- LXEOLexeo Therapeutics Up
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
